Evidence map›Paper›PMID 38454322›Full record

ArticleMolecular medicine (Cambridge, Mass.)2024

Artemisinin ameliorates cognitive decline by inhibiting hippocampal neuronal ferroptosis via Nrf2 activation in T2DM mice.

Bo Wang, Sheng Zhu, Miao Guo, Run-Dong Ma, Ya-Ling Tang, Ya-Xiong Nie, Hong-Feng Gu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Bo Wang *Institute of Anesthesiology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Sheng Zhu *Department of Nuclear Medicine, Affiliated Hospital of Xiangnan University, No. 25 Renmin West Road, Beihu District, Chenzhou, 423001, Hunan, China.
Miao GuoDepartment of Physiology and Institute of Neuroscience, Key Laboratory of Hunan Province for Major Brain Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Run-Dong MaInstitute of Anesthesiology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Ya-Ling TangDepartment of Physiology and Institute of Neuroscience, Key Laboratory of Hunan Province for Major Brain Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Ya-Xiong NieInstitute of Anesthesiology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Hong-Feng GuDepartment of Physiology and Institute of Neuroscience, Key Laboratory of Hunan Province for Major Brain Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. ghf513@sina.com.ORCID 0009-0004-2884-8246
University of South China · CNXiangnan University · CN

Funding

Clinical Medical Technology Innovation Guidance Project of Hunan Province 2021SK51813the key program of Educational Commission of Hunan Province, China 21A0273the National Natural Science Foundation of China 81500349the Natural Science Foundation of Hunan Province, China 2022JJ30509the Natural Science Foundation of Hunan Province, China 2022JJ30534
6 · The paper itself

Abstract

backgroundNeuronal ferroptosis plays a critical role in the pathogenesis of cognitive deficits. The present study explored whether artemisinin protected type 2 diabetes mellitus (T2DM) mice from cognitive impairments by attenuating neuronal ferroptosis in the hippocampal CA1 region.

methodsSTZ-induced T2DM mice were treated with artemisinin (40 mg/kg, i.p.), or cotreated with artemisinin and Nrf2 inhibitor MEL385 or ferroptosis inducer erastin for 4 weeks. Cognitive performance was determined by the Morris water maze and Y maze tests. Hippocampal ROS, MDA, GSH, and Fe

resultsArtemisinin reversed diabetic cognitive impairments, decreased the concentrations of ROS, MDA and Fe

conclusionArtemisinin effectively ameliorates neuropathological changes and learning and memory decline in T2DM mice; the underlying mechanism involves the activation of Nrf2 to inhibit neuronal ferroptosis in the hippocampus.

Indexed as

ArtemisininsCognitive DysfunctionDiabetes Mellitus, Type 2FerroptosisAnimalsHippocampusMiceNeuronsNF-E2-Related Factor 2Reactive Oxygen SpeciesartemisininArtemisininsNF-E2-Related Factor 2Reactive Oxygen SpeciesArtemisininDiabetic cognitive deficitFerroptosisHippocampusNrf2

Identifiers

PMID38454322
PMCPMC10921734
OpenAlexW4392549925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.